NCI Director's Report: Opportunities and realities for clinical cancer research

W. Kimryn Rathmell, M.D., Ph.D.

Director, National Cancer Institute

53rd Meeting of the Clinical Trials and Translational Research Committee March 13, 2024

> @NCIDirector @TheNCI

Today's Topics:

Brief introduction
 Budget outlook
 Research highlights
 Q&A



A little about me

Background in brief:

- Scientist
- Clinician, oncologist
- Educator/mentor
- Health care management and administration
- Leader
- Advocacy
- Basketball player (and aficionado)

Principles I value



Listening, openness



Teamwork, collaboration



Solving complex problems

Patient story





A story about science, collaboration, and impact



Meeting and treating "Paul"





Connecting with advocates through social media

Think tank meeting



Creating RMC Alliance



IMPACT: Improved health outcomes, clinical trials, information, visibility, education, grants




Budget outlook



Where we are today (for FY24)



Potential lapses in appropriation averted: September 30, 2023 November 17, 2023 February 2, 2024 March 8





Interim grant policies have been set. Final adjustments will be made when NCI receives a full-year appropriation.



NCI's budget is determined within the federal budget ecosystem

alongside many other national priorities

Appropriations bills for FY24


Completed on March 9

- Agriculture, Rural Development, FDA, and Related Agencies
- Commerce, Justice, Science, and Related Agencies
- Energy and Water Development
- Interior, Environment, and Related Agencies
- Military Construction, Veterans Affairs, and Related Agencies
- Transportation, Housing and Urban Development, and Related Agencies

Pending (continuing resolution through March 22)

- Defense
- · Financial Services and General Government
- Homeland Security
- Labor, Health and Human Services, Education, and Related Agencies
- Legislative Branch
- State, Foreign Operations, and Related Programs

How NCI spends its budget



Major areas of NCI's work span more than one of the categories in the chart:


- Clinical trials
- Training & career development
- Basic science

These efforts are funded through multiple mechanisms and approaches, including:

9

- Intramural research
- Extramural research
- National networks
- Research project grants

FY22 Total Award Amount for RPGs by Category



CSO category of Treatment is the largest total category followed closely by Biology

NATIONAL CANCER INSTITUTE

Method note: Awards can be classified in more than one category. When an award is classified in more than one category, the award's total costs are counted toward all categories associated with the award. Classification is done at the sub-project level for multi-component awards. Includes all awarded NCI administered RPGs.




NCI has been funding more awards year over year

8.000 7,000 6,000 Dollars (in millions) 5,000 4,000 3,000 2,000 1,000 0 2019 2021 2022 2023 2020 **Fiscal Year Cancer Moonshot funding** Enacted

NCI Budget History (appropriations)


FY19 – FY23

NCI Grant Awards (competing and non-competing) FY19 – FY23



11

DCTD Extramural Grant Award Amounts: FY13-FY22



----- All Extramural ----- non-RPGs ----- RPGs ----- R01 Eq.

Analysis includes NCI administered *extramural grants* from FY13-FY22. Co-funding is not considered. R01 Eq. refers to a subset of RPGs.

12



Example: Opportunities for Collaborative Research at the NIH Clinical Center (U01 Program)



Opportunities for Collaborative Research at the NIH Clinical Center (U01 Program)

Purpose of U01 funding opportunity:

- Support collaboration between intramural and extramural investigators
- Allow extramural investigators to take advantage of the NIH Clinical Center – unique resources and patient populations

FY13- FY24	No. of Applications Received	No. of Awards Granted	% Accepted
NIH	302	63	21%
NCI	134	25	19%

NCI administers:

- 44% of all U01 applications
- 40% of all U01 competing awards

The number of NCI U01 applications has remained consistent since 2014.

14

U01 Program: Examples that tap the Clinical Center

- Unique biospecimen resources
- State of the art imaging and testing facilities
- Rare disease populations
- U01 is an important mechanism for collaboration between the intramural and extramural community



NIH Clinical Center


15

What it would cost to do what we expect for cancer

	NCI's Professional Judgment Budget Proposal	Actual NCI Budget
FY 2024	\$9.988B	?
FY 2025	\$11.466B	?

• FY 2023 total appropriation: \$7.3 billion

FY 2025 President's Budget Proposal released this week



FY 2025 President's Budget Proposal \$7.839B (discretionary) + \$1.448B (mandatory) = **\$9.287B total**

- Proposes \$716M of discretionary funding for Cancer Moonshot
- Proposes \$1.448B of mandatory funding for Cancer Moonshot



NCI Fiscal Year 2025 Professional Judgment Budget Proposal



Leading Progress against Cancer

NCI Fiscal Year 2025 Professional Judgment Budget Proposal

View the budget proposal and the Director's Message: www.cancer.gov/research/leading-progress

Highlighted Scientific Opportunities

- Improving patients' lives through symptom science research
- Revolutionizing cancer clinical trials
- Clarifying the impact of the environment on cancer risk
- Harnessing the power of cancer data
- Unraveling the complexity of cancer metastasis

A "flat" budget is not truly flat – it is a reduction

Why?

- End of 21st Century Cures Act funding for the Cancer MoonshotSM
- Research costs and salaries
 increase (COLA)
- Non-negotiable expenses for NCI increase each year by \$75M to \$100M
- RPG cost increases \$250M annually to fully fund at current levels

Available levers to manage constrained budget:

Research Project Grants (RPGs)	•	Decrease the "payline" for new awards Fund non-competing awards < 100%
Cancer Center Support Grants (CCSGs)	•	Forgo increases for competing renewals Decreases to non-competing CCSGs
Cancer Training Awards	•	Fewer new awards (F's, K's, T's)
Specialized Programs of Research Excellence (SPORE) Grants	•	Fewer new awards Decreases to non-competing awards
Intramural Research Program	• • •	Planned budget reductions Reduced hiring Decreased contractor utilization Trim programs

Resources about NCI budget and appropriations



Sept. 6, 2023 NCAB meeting: NCI budget overview www.videocast.nih.gov/watch=52268&start=3723



Updated budget and appropriations page: www.cancer.gov/about-nci/budget

NCI's Fiscal Year 2024 Budget Challenges and Interim Paylines Explained

Subscribe

November 15, 2023, by NCI Acting Director, Dr. Douglas R. Lowy





NCI *Bottom Line* blog post on FY24 budget outlook: www.cancer.gov/grants-training/nci-bottom-line-blog/



Leading Progress against Cancer NCI Fiscal Year 2025 Professional Judgment Budget Proposal

NCI Fiscal Year 2025 Professional Judgment Budget Proposal: www.cancer.gov/research/leading-progress

National Cancer Plan

Everyone has a role.

8 goals:

Prevent Cancer Detect Cancers Early Develop Effective Treatments Deliver Optimal Care Maximize Data Utility Eliminate Inequities Optimize the Workforce Engage Every Person

eliminate Ine. Changing how we know cancer today. **Reducing cancer** *mortality*. Improving lives of people with cancer. Optim.

THE PRESIDENT AND FIRST LADY'S

CANCER MOONSHOT

ENDING CANCER AS WE KNOW IT

Goals of the reignited Cancer Moonshot

- Reduce U.S. cancer mortality rate by 50% by 2047
- Improve the experience of people and their families living with and surviving cancer



Recent wins – some examples



Recent wins and accomplishments in cancer research

- First FDA approval of cell therapy in solid tumors (tumor-infiltrating lymphocytes, TILs, for advanced melanoma)
- New "SHIP" Trial Network announced: Self-collection for HPV testing to Improve Cervical Cancer Prevention
- New Cancer Screening Research Network launched
- ✓ New NCI Virtual Clinical Trials Office launched
- ✓ Announcement of new Cancer Grand Challenges teams and challenges

(More details in following slides.)

More at NCI Cancer Currents blog: www.cancer.gov/blog



Breakthrough in cellular therapy for solid tumors – pioneered by decades of NCI research

Tumor-infiltrating lymphocytes (TILs) for advanced melanoma


- First-ever FDA approval of cellular therapy for solid tumors
- Marks a new era of cancer treatment

Exemplary model of collaboration and translational science: basic science > clinical research > treatment development

Considerations: Scaling; application to other cancers; access



Pioneered by Dr. Steven A. Rosenberg NCI Center for Cancer Research ~40 years of basic science research



Contributes to National Cancer Plan goals:



Breakthrough in cellular therapy for solid tumors – pioneered by decades of NCI research

First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma

Subscribe

March 5, 2024, by Carmen Phillips

In an event more than three decades in the making, the Food and Drug Administration (FDA) has approved lifileucel (Amtagvi), the first treatment for cancer that uses immune cells called tumor-infiltrating lymphocytes, or TILs. Announced on February 16, the agency's decision also makes lifileucel the first cellular therapy to be approved for a solid tumor, the skin cancer melanoma.

The agency's accelerated approval covers the use of lifileucel for people with advanced melanoma that has gotten worse after treatment with certain immunotherapy drugs or targeted therapies.



FDA has approved the first treatment for cancer that uses tumor-infiltrating lymphocytes, or TILs. Credit: National Cancer Institute



Cancer Currents: An NCI Cancer Research Blog Subscribe

Read full story at: www.cancer.gov/blog

New "SHIP" trial network on self-sampling for cervical cancer prevention announced at White House (January 25, 2024)



Readout of White House Cervical Cancer Forum

Last week, the Biden Cancer Moonshot hosted the White House Month and spur action on education, prevention, early detection, and

As part of the Forum, National Cancer Institute (NCI) Director Kimryn Rathmell announced a new NCI-supported trial to drive progress on cervical cancer prevention. The brand new 'Last Mile' Initiative, Self-collection for HPV testing to Improve Cervical Cancer Prevention (SHIP) Trial Network *↗* aims to test the performance of multiple self-collection devices for HPV, the leading driver of cervical cancer, so that cervical cancer screening can be brought closer to the

people in the communities that are behind on screening.

www.whitehouse.gov/briefing-room

Self-collection for HPV testing to Improve **Cervical Cancer Prevention (SHIP) Trial Network**

- Great example of:
 - Broad collaboration within research and beyond, including federal and private sector
 - Addressing disparities
 - **Engaging with the community**, beneficiaries of research

Contributes to National Cancer Plan goals:



First large scale network on cancer screening launched

NCI Press Release

NIH launches research network to evaluate emerging cancer screening technologies

February 21, 2024



Goal: To evaluate emerging cancer screening technologies (e.g., multi-cancer detection blood tests) – with the ultimate aim to save lives.

CSRN is the first large scale network to focus on cancer screening.



Contributes to National Cancer Plan goals

New NCI Virtual Clinical Trials Office pilot program

NCI Media Advisory

NIH to address dwindling clinical trial patient enrollment with centralized staffing support

February 29, 2024



What:

• Centralized, remote staff support for NCI-supported clinical trials activities

Aims:

 Improve accrual and retention rate to trials – by addressing staffing challenges and burdens of clinical research

Status:

• 6 sites selected for initial pilot phase

Contributes to National Cancer Plan goals:



Childhood Cancer Data Initiative (CCDI) continues to make progress toward National Cancer Plan goals

- Recent progress
 - Molecular Characterization Initiative (MCI) expands enrollment to children newly diagnosed with advanced stage neuroblastoma
 - Includes Renal Medullary Carcinoma (RMC)
- Upcoming events
 - March CCDI Community Forum (3/18) interactive Q&A for community input



CCDI continues to make important contributions to National Cancer Plan goals

WHAT IS THE CCDI MOLECULAR CHARACTERIZATION INITIATIVE?

- Provides state-of-the-art **molecular characterization at time of diagnosis** to inform optimal treatment decisions.
- A national collaboration between:
 - Childhood cancer community (including COG)
 - ✓ Advocates
 - ✓ Pediatric oncologists
 - ✓ Researchers
 - ✓ Data scientists
 - ✓ Children, adolescents, and young adults with cancer
 - ✓ Families



Cancer Grand Challenges New teams announced

Five teams, four challenges:

Reducing cancer inequities

Understanding mechanisms of early-onset cancers

Developing drugs for **solid tumors in children**

Broadening knowledge about how **T cells** recognize cancer cells



About Cancer Grand Challenges

- Global funding initiative to advance **bold cancer research**
- Co-founded by NCI and Cancer Research UK (CRUK) in 2020
- Each team receives up to \$25M over five years
- New awardees:
 - Span 12 countries
 - Represent 45 institutions
 - Include ~70 investigators and researchers

What I need from CTAC...



Guidance on the clinical research portfolio

- NCTN/NCORP
- ETCTN
- CSRN
- NCI Clinical Center
- Funded clinical research portfolio, SPOREs, CCSG
- Training in clinical research (T32, K12, others)
- Community engagement in clinical research priority setting





- Are there areas we are missing?
- Are we in spaces that are better served by foundations or industry?
- Are we resourcing programs so that they can be successful?

Closing thoughts

Given the budget realities...

We must work together – creatively, collaboratively, and efficiently – to make the best decisions given the tough reality.

Our work is ultimately for the benefit of people, patients and families touched by cancer.

We will use the National Cancer Plan as our roadmap toward ending cancer as we know it.



Working together to assemble puzzle. Image generated by AI.

Thank You!

www.cancer.gov www.cancer.gov/espanol 1-800-4-CANCER NClinfo@nih.gov @NCIDirector @TheNCI

